Key result
Pre-existing anti-cardiac troponin I antibodies correlate with greater LVEDV and LVESV following AMI.
Why the study?
Anti-cardiac troponin I antibodies have been demonstrated in ACS patients, but their clinical relevance and impact on patient outcomes remain to be elucidated.
Does the presence of anti-cardiac troponin I antibodies correlate with left ventricular remodeling in patients with acute myocardial infarction?
Cohort (n=23)
Does the presence of anti-cardiac troponin I antibodies correlate with left ventricular remodeling in patients with acute myocardial infarction?
The presence of anti-cardiac troponin I antibodies in AMI patients correlates with increased left ventricular volumes, suggesting a potential role in predicting post-MI cardiac remodeling.
Answers are grounded in this paper and cite their sources.
cTnIAb positivity may flag higher remodeling risk post-MI; hypothesis-generating and requires prospective validation before clinical use.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
González-Rojas et al. (2026) conducted a cohort in acute myocardial infarction (AMI) (n=23). Anti-cardiac troponin I antibodies (cTnIAb) vs. No detectable cTnIAb was evaluated on Left ventricular end-diastolic volume (LVEDV) and left ventricular end-systolic volume (LVESV). In patients with acute myocardial infarction, pre-existing anti-cardiac troponin I antibodies positively correlated with greater left ventricular end-diastolic and end-systolic volumes.
Synapse has enriched 10 related papers. Consider them for comparative context: